0001621227false00-000000000016212272024-09-232024-09-23

​

​

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​

FORM 8-K

​

Current Report

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

​

Date of Report (Date of earliest event reported): September 23, 2024

​

ADAPTIMMUNE THERAPEUTICS PLC

(Exact name of registrant as specified in its charter)

​

​

​

​

​

​

England and Wales

​

1-37368

​

Not Applicable

(State or other jurisdiction of
incorporation)

​

(Commission File Number)

​

(IRS Employer Identification No.)

​

60 Jubilee Avenue, Milton Park

Abingdon, Oxfordshire OX14 4RX

United Kingdom

(Address of principal executive offices, including zip code)

​

(44) 1235 430000

(Registrant’s telephone number, including area code)

​

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

​

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

​

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

​

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

​

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​

Securities registered pursuant to Section 12(b) of the Act:

​

Title of each class

​

Trading Symbol

​

Name of each exchange on which
registered

American Depositary Shares, each representing 6 Ordinary Shares, par value £0.001 per share

​

ADAP

​

The Nasdaq Global Select Market

​

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

​

Emerging growth company ☐

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐

​

​

​

​

​

​

Item 1.01Entry into a Material Definitive Agreement.

On September 23, 2024, Adaptimmune Therapeutics plc (the “Company”) entered into a Mutual Release and Resolution Agreement (the “Agreement”) with Genentech Inc and F. Hoffmann-La Roche Ltd, (together “Genentech”). The parties entered into the Agreement following notice of termination of their Collaboration and License Agreement dated September 3, 2021 (the “Collaboration Agreement”) on April 8, 2024 in order to, among other things, resolve and release each party from any and all past, present and future disputes, claims, demands and causes of action, whether known or unknown, related to the Collaboration Agreement in any way. Under the terms of the Agreement, Genentech will pay the Company $12,500,000, and the Collaboration Agreement will be terminated. The Agreement is effective as of September 23, 2024 following which each party to the Agreement is expressly released from any and all past, present and future disputes, claims, demands and causes of action, whether known or unknown, related to the Collaboration Agreement in any way.

The foregoing description of the Agreement is only a summary of certain material terms thereof, and does not purport to be complete. The description is qualified in its entirety by reference to the complete text of the Agreement to be filed with the Securities and Exchange Commission in connection with the Company’s Form 10-Q for the quarter ended September 30, 2024.

​

Item 9.01    Financial Statements and Exhibits.

(d)  Exhibits.

Exhibit No.

    

Description of Exhibit

​

​

​

104

​

Cover Page Interactive Date File (embedded within the Inline XBRL document)

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

​

​

​

ADAPTIMMUNE THERAPEUTICS PLC

​

​

​

Date: September 23, 2024

By:

/s/ Margaret Henry

​

​

Name:

Margaret Henry

​

​

Title:

Corporate Secretary

​

​

v3.24.3
Document and Entity Information
Sep. 23, 2024
Document and Entity Information [Abstract]  
Document Type 8-K
Document Period End Date Sep. 23, 2024
Entity File Number 1-37368
Entity Registrant Name ADAPTIMMUNE THERAPEUTICS PLC
Entity Incorporation, State or Country Code X0
Entity Tax Identification Number 00-0000000
Entity Address, Address Line One 60 Jubilee Avenue
Entity Address, Adress Line Two Milton Park
Entity Address, City or Town Abingdon, Oxfordshire
Entity Address, Postal Zip Code OX14 4RX
Entity Address, Country GB
City Area Code 44
Local Phone Number 1235 430000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security American Depositary Shares, each representing 6 Ordinary Shares, par value £0.001 per share
Trading Symbol ADAP
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001621227
Amendment Flag false
Grafico Azioni Adaptimmune Therapeutics (NASDAQ:ADAP)
Storico
Da Ott 2024 a Nov 2024 Clicca qui per i Grafici di Adaptimmune Therapeutics
Grafico Azioni Adaptimmune Therapeutics (NASDAQ:ADAP)
Storico
Da Nov 2023 a Nov 2024 Clicca qui per i Grafici di Adaptimmune Therapeutics